News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Christina Baik

Articles by Christina Baik

1 expert is featured in this series

Safety and efficacy results of the Phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations

ByChristina Baik

June 23rd 2026

Phase II data show Silevertinib boosts responses and brain control in treatment‑naive EGFR non‑classical NSCLC, with manageable rash/diarrhea.

Latest Updated Articles

Trending on OncLive

FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma

Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL

Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL

Breaking Treatment Barriers: Therapy for Advanced (Metastatic) EGFR-Mutated Non-Small Cell Lung Cancer After Targeted Therapy and Chemotherapy

Dr Shadman on uMRD Rates With Sonrotoclax Plus Zanubrutinib in Frontline CLL/SLL